Literature DB >> 23925669

Medication overuse headache: history, features, prevention and management strategies.

Joel R Saper1, Arnaldo Neves Da Silva.   

Abstract

Medication overuse headache (MOH) is a daily, or almost daily, headache form that arises from overuse of one or more classes of migraine-abortive or analgesic medication. The main classes of drugs that cause MOH are opioids, butalbital-containing mixed analgesics, triptans, ergotamine tartrate derivatives, simple analgesics (except for plain aspirin), and perhaps non-steroidal anti-inflammatory drugs. MOH can be debilitating and results from biochemical and functional brain changes induced by certain medications taken too frequently. At this time, migraine and other primary headache disorders in which migraine or migraine-like elements occur seem exclusively vulnerable to the development of MOH. Other primary headache disorders are not currently believed to be vulnerable. The treatment of MOH consists of discontinuation of the offending drug(s), acute treatment of the withdrawal symptoms and escalating pain, establishing a preventive treatment when necessary, and the implementation of educational and behavioral programs to prevent recidivism. In most patients, MOH can be treated in the outpatient setting but, for the most difficult cases, including those with opioid or butalbital overuse, or in patients with serious medical or behavioral disturbances, effective treatment requires a multidisciplinary, comprehensive headache program, either day-hospital with infusion or an inpatient hospital setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23925669     DOI: 10.1007/s40263-013-0081-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  69 in total

1.  Medication overuse headache: type I and type II.

Authors:  J R Saper; A E Lake
Journal:  Cephalalgia       Date:  2006-10       Impact factor: 6.292

Review 2.  Borderline personality disorder and the chronic headache patient: review and management recommendations.

Authors:  Joel R Saper; Alvin E Lake
Journal:  Headache       Date:  2002 Jul-Aug       Impact factor: 5.887

3.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

4.  Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache.

Authors:  J Jones; D Sklar; J Dougherty; W White
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

5.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

6.  Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design.

Authors:  Signe B Munksgaard; Lars Bendtsen; Rigmor H Jensen
Journal:  Cephalalgia       Date:  2012-06-29       Impact factor: 6.292

7.  Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study.

Authors:  Kasja Rabe; Lutz Pageler; Charly Gaul; Christian Lampl; Torsten Kraya; Stefanie Foerderreuther; Hans-Christoph Diener; Zaza Katsarava
Journal:  Cephalalgia       Date:  2012-10-23       Impact factor: 6.292

Review 8.  Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat.

Authors:  R Björkman
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1995

Review 9.  Medication-overuse headache.

Authors:  Stewart J Tepper
Journal:  Continuum (Minneap Minn)       Date:  2012-08

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  12 in total

Review 1.  Medication overuse headache.

Authors:  Valerie Cheung; Farnaz Amoozegar; Esma Dilli
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

2.  Migraine attacks in the pharmacy: a survey in Piedmont, Italy.

Authors:  P Brusa; G Allais; G Bussone; S Rolando; M Giaccone; M Aguggia; C Benedetto
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

3.  Medication-overuse headache.

Authors:  Andrew Micieli; Jennifer Robblee
Journal:  CMAJ       Date:  2018-03-12       Impact factor: 8.262

4.  Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.

Authors:  Bixi Gao; Qiran Lu; Rong Wan; Zilan Wang; Yanbo Yang; Zhouqing Chen; Zhong Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-02       Impact factor: 3.000

5.  Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse.

Authors:  Maria Lurenda Westergaard; Ebba Holme Hansen; Charlotte Glümer; Rigmor Højland Jensen
Journal:  Eur J Clin Pharmacol       Date:  2015-05-14       Impact factor: 2.953

6.  Triptans disrupt brain networks and promote stress-induced CSD-like responses in cortical and subcortical areas.

Authors:  L Becerra; J Bishop; G Barmettler; Y Xie; E Navratilova; F Porreca; D Borsook
Journal:  J Neurophysiol       Date:  2015-10-21       Impact factor: 2.714

Review 7.  Neuroimaging Findings in Patients with Medication Overuse Headache.

Authors:  Tzu-Hsien Lai; Shuu-Jiun Wang
Journal:  Curr Pain Headache Rep       Date:  2018-01-16

8.  Cost-effectiveness analysis of non-invasive vagus nerve stimulation for the treatment of chronic cluster headache.

Authors:  James Morris; Andreas Straube; Hans-Christoph Diener; Fayyaz Ahmed; Nicholas Silver; Simon Walker; Eric Liebler; Charly Gaul
Journal:  J Headache Pain       Date:  2016-04-22       Impact factor: 7.277

9.  Cervical non-invasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: a prospective observational cohort study.

Authors:  Thomas M Kinfe; Bogdan Pintea; Sajjad Muhammad; Sebastian Zaremba; Sandra Roeske; Bruce J Simon; Hartmut Vatter
Journal:  J Headache Pain       Date:  2015-12-03       Impact factor: 7.277

10.  Biofeedback in the prophylactic treatment of medication overuse headache: a pilot randomized controlled trial.

Authors:  Marialuisa Rausa; Daniela Palomba; Sabina Cevoli; Luana Lazzerini; Elisa Sancisi; Pietro Cortelli; Giulia Pierangeli
Journal:  J Headache Pain       Date:  2016-09-22       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.